Confirmed Supporters



Confirmed Supporters

ISH 2018 would like to thank the following companies for their generous support:



Confirmed Exhibitors

Alexion | Booth # 600
Alexion is a global biopharmaceutical company focused on serving patients with devastating and rare diseases. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to develop and deliver therapies that will transform their lives. (
Amgen Canada | Booth # 502
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients. (
Aplastic Anemia and Myelodysplasia Association of Canada | Table # C
The Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC) is a federally incorporated and registered national charity with the goal of providing a support network for every Canadian patient, caregiver and healthcare provider dealing with aplastic anemia, myelodysplasia or PNH. AAMAC is led by a volunteer board of directors and a distinguished team of medical advisors from across Canada. (
Best Theratronics Ltd. | Booth # 401
Best® Theratronics leads the industry in blood irradiation. Our Gammacell® line is the “Gold Standard” in countless clinics worldwide, and our latest in x-ray irradiation, the Raycell® Mk2, delivers superior performance and uniformity. Now introducing the new Raycell® Mk1 with its own water supply, compact size, and the ability to irradiate a 60 ml syringe. (
Binding Site | Booth # 409
Binding Site is a diagnostic company that manufactures and distributes tests such as Freelite(R) serum free light chain tests, used as an aid in the diagnosis and monitoring of Multiple Myeloma and related plasma cell disorders, and Hevylite(R) tests for quantitation of intact heavy/light chain combinations to be used for monitoring previously diagnosed Multiple Myeloma patients. (
BPL | Booth # 300
Bio Products laboratory, Limited (BPL) is a leading manufacturer of plasma-derived protein therapies with global headquarters in Elstree, England, US headquarters in Durham, NC, and a presence in more than 45 countries worldwide. The company has over 60 years of experience developing and manufacturing plasma-derived therapies and currently markets a wide range of products including coagulation factor, human immunoglobulin, and albumin. (
Canadian Hematology Society | Table # G
The CHS, founded in 1971, represents Canadian hematologists. The organization’s main goals are to maintain the integrity and vitality of the hematology specialty in Canada, to encourage and reward scholarly research, and to provide a forum for communication and support for colleagues in the community and in academic settings. (
Hoffmann-La Roche Limited | Booth # 302
Doing now what patients need next. We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world. (
Hospital Information Services (Canada) | Table # B
Hospital Information Services (Canada) is part of an international network disseminating authoritative information regarding clinical strategies to avoid allogeneic blood transfusion and facilitating access to health care for patients who are Jehovah’s Witnesses. Professional educational materials, outlining cost-effective management of hemorrhage and anemia without allogeneic transfusion, are available without charge. (
ISH 2020 Thailand | Booth # 201
Attend the 38th World Congress of International Society of Hematology (ISH 2020) to hear the world-renowned experts present the latest updates in hematology researches and translate them into patient care improvements. This is a great opportunity to share experience, exchange knowledge and network with physicians and scientists around the world. September 13-17, 2020, Bangkok, Thailand. (
Janssen | Booth # 403
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We are Janssen. We collaborate with the world for the health of everyone in it. (
Jazz Pharmaceuticals | Booth # 510
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in other therapeutic areas where we can meaningfully address serious medical needs. (
LifeLabs | Booth # 411
LifeLabs has been serving the healthcare needs of Canadians for more than 50 years. Today, LifeLabs performs more than 110 million laboratory tests every year with continual innovation in testing services as it helps healthcare providers diagnose, treat, monitor and prevent disease in patients. (
Mayo Clinic Laboratories | Booth # 602
Mayo Medical Laboratories is a global reference laboratory bringing Mayo Clinic diagnostic excellence to physicians and patients around the world and providing excellent reference laboratory services with over 23 million tests performed from around the world. (
MDS Alliance | Table # D
The MDS Alliance is an international umbrella organisation that aims to ensure MDS patients, regardless of where they live, have access to the best multi-professional care. We also aim to provide member organisations, patients and healthcare teams with the resources and the latest information about MDS, including current treatment options, large international projects and events of Interest to the whole community. (
The MDS Foundation, Inc. | Table # A
The MDS Foundation, Inc. (MDSF) is an international organization devoted to the support and education of patients and healthcare providers with innovative research in the fields of MDS and related myeloid neoplasms in order to accelerate progress leading to the control and cure of these diseases. (
Methapharm Specialty Pharmaceuticals | Booth # 310
Methapharm is a privately held specialty pharmaceutical company with a focus on the acquisition, licensing and promotion of healthcare products in North America. Methapharm focuses on several therapeutic areas in Canada, but has a particular interest in Respiratory, Imaging, Hospital and Prescription Products. (
Novartis Oncology | Booths # 500 & 501
Novartis Oncology is a global leader in improving outcomes for patients. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients. (
NRBDO | Table # F
The Network of Rare Blood Disorder Organizations (NRBDO)/Réseau des associations vouées aux troubles sanguins rares (RAVTSR) is a coalition of national patient groups. We work and advocate together toward high quality, effective, accessible, interdisciplinary care for all Canadians affected by rare blood disorders. (
Pfizer Oncology | Booths # 312 & 512
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application. (
Recordati Rare Diseases Canada Inc. | Booth # 509
Recordati Rare Diseases Canada Inc. is part of the Recordati Group (established 1926), a public global pharmaceutical company committed to the development of unique treatments for rare diseases. Recordati Rare Diseases Canada Inc. proudly announces PANHEMATIN® (hemin for injection, DIN 02478765) NOW APPROVED in Canada. (
  Stemline Therapeutics | Booth # 511
Stemline Therapeutics is developing three clinical candidates: ELZONRISTM (tagraxofusp; SL-401), SL-801, and SL-701. ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123), was granted breakthrough therapy designation in blastic plasmacytoid dendritic cell neoplasm (BPDCN). A BLA is under review. Additional ELZONRIS clinical trials are ongoing in CMML and MF. (
Takeda | Booth # 503
Takeda Canada is delivering better health for Canadians through leading innovations in gastroenterology and oncology. Takeda’s top priority is the health of Canadians; their well-being is central to our work and drives our commitment to deliver a diverse portfolio of innovative treatments in specialty care. (
Taylor & Francis Group | Table # E
Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Hematology aims to bridge the interests and practices of both those carrying out laboratory work and those whose main inclination is towards patient care. The journal provides a forum where the clinical aspects of any published material will be emphasised. (

Exhibit Floor Plan

Please click on the image below to view the live version of the Exhibit Floor Plan.

(click image to view live Floor Plan)